Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | UGCG | Q16739 | 1/20 | 0.44 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 4/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16727733 | 0.99 | L3MBTL1 (0.56) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL15861737 | 0.89 | TDP1 (0.47) | L3MBTL1TDP1CA1CA2CALM1 | |
| SCHEMBL16727736 | 0.85 | L3MBTL1 (0.57) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL16727731 | 0.84 | L3MBTL1 (0.56) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL16727730 | 0.82 | L3MBTL1 (0.53) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL17032624 | 0.82 | L3MBTL1 (0.53) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL9234752 | 0.81 | L3MBTL1 (0.62) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL10879554 | 0.81 | NR5A1 (0.51) | MEN1KMT2A | |
| SCHEMBL16614394 | 0.80 | L3MBTL1 (0.57) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL27089910 | 0.80 | L3MBTL1 (0.55) | L3MBTL1TDP1GBA1UGCGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318862-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015048268-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318862-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | DGKZ, DGKG, DNAJA3 | L3MBTL1 4273/4885TDP1 3703/4885GBA1 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.